These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32621739)

  • 21. Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study.
    Kevorkian JP; Riveline JP; Vandiedonck C; Girard D; Galland J; Féron F; Gautier JF; Mégarbane B
    J Infect; 2021 Jan; 82(1):e22-e24. PubMed ID: 32888976
    [No Abstract]   [Full Text] [Related]  

  • 22. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.
    Kow CS; Hasan SS
    Chest; 2021 May; 159(5):2108-2109. PubMed ID: 33965134
    [No Abstract]   [Full Text] [Related]  

  • 24. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
    Berton AM; Prencipe N; Giordano R; Ghigo E; Grottoli S
    J Endocrinol Invest; 2021 Apr; 44(4):873-875. PubMed ID: 32514902
    [No Abstract]   [Full Text] [Related]  

  • 26. From publications to every day clinical practice: tocilizumab in patients with severe COVID-19.
    Galvalisi N; Pagotto V; Tudanca V; Brunetti P; Tornatore C; Villar L; Allalla F; Ferraro H; Schejtman A; Rotryng F
    Medicina (B Aires); 2022; 82(5):659-666. PubMed ID: 36220021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing COVID-19 treatments: what we should never forget.
    Tunesi S; Bourgarit A
    J Infect; 2020 Aug; 81(2):e85. PubMed ID: 32405110
    [No Abstract]   [Full Text] [Related]  

  • 29. Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
    Subramanian K; Nalli A; Senthil V; Jain S; Nayak A; Bhat A
    Adv Ther; 2020 Oct; 37(10):4107-4131. PubMed ID: 32809210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
    Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
    Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19.
    Kawamata T; Tanino Y; Nikaido T; Minemura H; Sato Y; Togawa R; Watanabe N; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Rikimaru M; Suzuki Y; Tsukada Y; Nakamura K; Kanemitsu K; Iseki K; Shibata Y
    J Infect Chemother; 2022 Dec; 28(12):1639-1644. PubMed ID: 36057415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal Perforation After Treatment With Tocilizumab : An Unexpected Consequence of COVID-19 Pandemic.
    Rojo M; Cano-Valderrama O; Picazo S; Saez C; Gómez L; Sánchez C; Sanz-Ortega G; Torres AJ
    Am Surg; 2020 Jun; 86(6):565-566. PubMed ID: 32683974
    [No Abstract]   [Full Text] [Related]  

  • 33. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
    Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
    PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Traditional Chinese Medicine as Potential Therapy for COVID-19.
    Li S; Liu C; Guo F; Taleb SJ; Tong M; Shang D
    Am J Chin Med; 2020; 48(6):1263-1277. PubMed ID: 32907358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab: From Rheumatic Diseases to COVID-19.
    Raiteri A; Piscaglia F; Granito A; Tovoli F
    Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study.
    Hu Q; Xu Y; Xiang Y; Wang B; Yuan Z; Shan Y; Zhang W; Wu N; Xia T; Li C; Xie W; Jia X; Yu Z; Bai L; Li Y
    Int J Biol Sci; 2021; 17(8):2124-2134. PubMed ID: 34131411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.
    Wang J; Yang W; Chen P; Guo J; Liu R; Wen P; Li K; Lu Y; Ma T; Li X; Qin S; Zhang Y; Wang Y
    PLoS One; 2021; 16(4):e0249481. PubMed ID: 33882090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019.
    Guisado-Vasco P; Aguarles Gorines J; Carralón González MM; Sotres Fernández G; Carnevali Ruiz D
    J Infect Dis; 2022 Aug; 226(1):1-5. PubMed ID: 35297493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.